ATE556712T1 - A2a antagonisten zur behandlung von motorischen störungen - Google Patents
A2a antagonisten zur behandlung von motorischen störungenInfo
- Publication number
- ATE556712T1 ATE556712T1 AT10005600T AT10005600T ATE556712T1 AT E556712 T1 ATE556712 T1 AT E556712T1 AT 10005600 T AT10005600 T AT 10005600T AT 10005600 T AT10005600 T AT 10005600T AT E556712 T1 ATE556712 T1 AT E556712T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- treatment
- hydrogen atom
- motor disorders
- substituted
- Prior art date
Links
- 208000019430 Motor disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005166981 | 2005-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE556712T1 true ATE556712T1 (de) | 2012-05-15 |
Family
ID=37498474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT10005600T ATE556712T1 (de) | 2005-06-07 | 2006-06-07 | A2a antagonisten zur behandlung von motorischen störungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7851478B2 (de) |
| EP (2) | EP2258372B8 (de) |
| JP (3) | JPWO2006132275A1 (de) |
| AT (1) | ATE556712T1 (de) |
| ES (1) | ES2385702T3 (de) |
| WO (1) | WO2006132275A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2089389A2 (de) | 2006-11-01 | 2009-08-19 | Bristol-Myers Squibb Company | Heterocyclische verbindungen als modulatoren der glucocorticoidrezeptor,- ap1- und/oder nf-kappa-b-aktivität |
| MX2011007678A (es) * | 2009-01-20 | 2011-08-08 | Schering Corp | Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa. |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| JP5843778B2 (ja) | 2009-11-09 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物、その調製およびその使用 |
| RU2625791C2 (ru) | 2010-02-05 | 2017-07-19 | Хептейрес Терапьютикс Лимитед | Производные 1,2,4-триазин-4-амина |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| JP6308346B2 (ja) * | 2013-05-31 | 2018-04-11 | 三菱自動車工業株式会社 | 車両の制御装置 |
| JP6381883B2 (ja) * | 2013-10-04 | 2018-08-29 | 国立大学法人千葉大学 | 不随意運動の予防及び／又は治療組成物 |
| CA3086282A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| EP3735413B1 (de) | 2018-01-04 | 2022-07-06 | Impetis Biosciences Ltd. | Tricyclische verbindungen, zusammensetzungen und medizinische anwendungen davon |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2020204024A1 (ja) * | 2019-04-03 | 2020-10-08 | テラ・ストーン株式会社 | チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法 |
| WO2022029063A1 (en) | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| CA2284737C (en) | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| AU756144B2 (en) | 1998-09-22 | 2003-01-02 | Kyowa Hakko Kogyo Co. Ltd. | (1,2,4)triazolo(1,5-c)pyrimidine derivatives |
| US20040152659A1 (en) | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| EP1177797A1 (de) | 1999-05-12 | 2002-02-06 | Fujisawa Pharmaceutical Co., Ltd. | Neue verwendung |
| JP2001302648A (ja) * | 2000-04-28 | 2001-10-31 | Kyowa Hakko Kogyo Co Ltd | ピペラジン誘導体の製造法 |
| MY132006A (en) | 2000-05-26 | 2007-09-28 | Schering Corp | ADENOSINE A2a RECEPTOR ANTAGONISTS |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| HUP0401777A3 (en) | 2001-10-15 | 2008-06-30 | Schering Corp | 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds |
| US6916811B2 (en) * | 2001-11-30 | 2005-07-12 | Schering Corporation | Adenosine A2a receptor antagonists |
| IL161573A0 (en) | 2001-11-30 | 2004-09-27 | Schering Corp | [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS |
| DE10159922A1 (de) | 2001-12-06 | 2003-06-26 | Gruenenthal Gmbh | Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate |
| BR0306919A (pt) | 2002-01-28 | 2004-11-09 | Kyowa Hakko Kogyo Kk | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento |
| TWI331036B (en) * | 2002-12-19 | 2010-10-01 | Schering Corp | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| DE602004018637D1 (de) * | 2003-04-09 | 2009-02-05 | Biogen Idec Inc | A2a-adenosinrezeptorantagonisten |
| AU2004233334B2 (en) | 2003-04-23 | 2010-08-12 | Merck Sharp & Dohme Corp. | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| ATE353331T1 (de) | 2003-10-28 | 2007-02-15 | Schering Corp | Verfahren zur herstellung substituierter 5-amino- pyrazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidin |
| WO2005054245A2 (en) * | 2003-12-01 | 2005-06-16 | Schering Corporation | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines |
| CA2622741A1 (en) * | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists |
-
2006
- 2006-06-07 EP EP10005600A patent/EP2258372B8/de not_active Not-in-force
- 2006-06-07 ES ES10005600T patent/ES2385702T3/es active Active
- 2006-06-07 EP EP06757137A patent/EP1902716A4/de not_active Withdrawn
- 2006-06-07 US US11/916,783 patent/US7851478B2/en active Active
- 2006-06-07 WO PCT/JP2006/311430 patent/WO2006132275A1/ja not_active Ceased
- 2006-06-07 JP JP2007520141A patent/JPWO2006132275A1/ja active Pending
- 2006-06-07 AT AT10005600T patent/ATE556712T1/de active
-
2012
- 2012-11-06 JP JP2012244147A patent/JP2013056911A/ja active Pending
-
2014
- 2014-08-27 JP JP2014172319A patent/JP2015007096A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2258372B1 (de) | 2012-05-09 |
| EP1902716A1 (de) | 2008-03-26 |
| JPWO2006132275A1 (ja) | 2009-01-08 |
| JP2015007096A (ja) | 2015-01-15 |
| EP2258372B8 (de) | 2012-12-19 |
| US7851478B2 (en) | 2010-12-14 |
| EP1902716A4 (de) | 2009-05-13 |
| JP2013056911A (ja) | 2013-03-28 |
| EP2258372A1 (de) | 2010-12-08 |
| ES2385702T3 (es) | 2012-07-30 |
| US20090105277A1 (en) | 2009-04-23 |
| WO2006132275A1 (ja) | 2006-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE556712T1 (de) | A2a antagonisten zur behandlung von motorischen störungen | |
| WO2005018557A3 (en) | Substituted pyridinones | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| PT1159279E (pt) | 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais | |
| MXPA05010621A (es) | Pirimidinonas sustituidas. | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EP1700856A4 (de) | Thiazolderivat | |
| DE602008004540D1 (de) | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel | |
| EP1757594A4 (de) | Chinazolinderivat | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| ATE450514T1 (de) | Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung | |
| WO2005111002A3 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| ATE357917T1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| MX2009004314A (es) | Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos. | |
| ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| BRPI0409376A (pt) | derivados de indeno como agentes farmacêuticos | |
| DE60237637D1 (de) | Thiadiazolinderivate zur Krebsbehandlung | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| WO2003057213A3 (en) | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor | |
| WO2006134486A3 (en) | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists | |
| NO20081103L (no) | 9-Aminoklarbonylsubstituerte derivater av glycylcykliner | |
| ATE488510T1 (de) | Heterocyclische derivate, deren herstellung und therapeutische verwendung | |
| WO2006114666A8 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES |